Regenxbio Inc
(NAS:RGNX)
$
9.92
-0.09 (-0.9%)
Market Cap: 491.49 Mil
Enterprise Value: 320.09 Mil
PE Ratio: 0
PB Ratio: 1.63
GF Score: 65/100 Regenxbio Inc at Chardan Genetic Medicines Conference (Virtual) Transcript
Oct 05, 2021 / 08:00PM GMT
Release Date Price:
$30.9
(-4.42%)
Matthew Barcus
Chardan Capital Markets, LLC. - Analyst
Good afternoon. I am Matthew Barcus, a Research Associate here at Chardan. It is my pleasure to introduce our next fireside chat guest. From REGENXBIO, we have Ken Mills, President and CEO. (Operator Instructions). Ken, thank you for joining us today.
Ken Mills
REGENXBIO Inc. - President & CEO
Thanks, Matt, for you and the Chardan team hosting us.
Questions & Answers
Matthew Barcus
Chardan Capital Markets, LLC. - Analyst
Great. Maybe to start things off, would you be able to provide us with an overview of REGENXBIO and the greater mission of the Company?
Ken Mills
REGENXBIO Inc. - President & CEO
Absolutely. REGENXBIO is an AAV gene therapy company focused on a broad pipeline of active clinical trials and an early pipeline of research and development programs. It's been a productive year for us so far this year. We've made really important progress across our clinical pipeline and expect a
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot